Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients

Multiple Sclerosis Journal

Volumn 19, Issue 11, 2013, Pages 1454-1461

  Selter, Rebecca C ^a   Biberacher, Viola ^a   Grummel, Verena ^a   Buck, Dorothea ^a   Eienbröker, Christian ^b   Oertel, Wolfgang H ^b   Berthele, Achim ^a   Tackenberg, Björn ^b   Hemmer, Bernhard ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

alpha4beta1 integrin; B cell homing; immunoglobulin G; immunoglobulin M; Multiple sclerosis; natalizumab

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS;

ALPHA4BETA1 INTEGRIN; B CELL HOMING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MULTIPLE SCLEROSIS; NATALIZUMAB;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; B-LYMPHOCYTES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 84884560189     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513477229     Document Type: Article

References (27)

1. Fabbri M, Bianchi E, Fumagalli L, et al. Regulation of lymphocyte traffic by adhesion molecules. Inflamm Res. 1999 ; 48: 239-246
2. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990 ; 60: 577-584
3. Alon R, Kassner PD, Carr MW, et al. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol. 1995 ; 128: 1243-1253
4. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
5. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
6. Zohren F, Toutzaris D, Klarner V, et al. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008 ; 111: 3893-3895
7. Bonig H, Wundes A, Chang KH, et al. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008 ; 111: 3439-3441
8. Lo CG, Lu TT, Cyster JG. Integrin-dependence of lymphocyte entry into the splenic white pulp. J Exp Med. 2003 ; 197: 353-361
9. Belnoue E, Tougne C, Rochat AF, et al. Homing and adhesion patterns determine the cellular composition of the bone marrow plasma cell niche. J Immunol. 2012 ; 188: 1283-1291
10. Carrasco YR, Batista FD. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. EMBO J. 2006 ; 25: 889-899
11. Lu TT, Cyster JG. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science. 2002 ; 297: 409-412
12. Krumbholz M, Meinl I, Kumpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008 ; 71: 1350-1354
13. Planas R, Jelcic I, Schippling S, et al. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol. 2012 ; 42: 790-798
14. Silvy A, Altevogt P, Mondiere P, et al. A role for the VLA-4 integrin in the activation of human memory B cells. Eur J Immunol. 1997 ; 27: 2757-2764
15. Berlin-Rufenach C, Otto F, Mathies M, et al. Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice. J Exp Med. 1999 ; 189: 1467-1478
16. Berlin C, Bargatze RF, Campbell JJ, et al. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell. 1995 ; 80: 413-422
17. Finke D, Acha-Orbea H, Mattis A, et al. CD4+CD3- cells induce Peyer's patch development: Role of alpha4beta1 integrin activation by CXCR5. Immunity. 2002 ; 17: 363-373
18. Vinuesa CG, Tangye SG, Moser B, et al. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol. 2005 ; 5: 853-865
19. Mora JR, von Andrian UH. Differentiation and homing of IgA-secreting cells. Mucosal Immunol. 2008 ; 1: 96-109
20. Villar LM, Garcia-Sanchez MI, Costa-Frossard L, et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol. 2012 ; 69: 191-197
21. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A. 2004 ; 101: 11064-11069
22. McMillan R, Longmire R, Yelenosky R. The effect of corticosteroids on human IgG synthesis. J Immunol. 1976 ; 116: 1592-1595
23. Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immun. 1978 ; 62: 162-166
24. Posey WC, Nelson HS, Branch B, et al. The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immun. 1978 ; 62: 340-348
25. Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G (IgG) subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukaemia. Leuk Lymphoma. 2012 ;:
26. Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013 ; 54: 99-104
27. Hopfinger G, Plessl A, Grisold W, et al. Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count. Leuk Lymphoma. 2008 ; 49: 2367-2369